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CIS-2,6-DISUBSTITUTED PIPERIDINES FOR 
THE TREATMENT OF PSYCHOSTIMULANT 
ABUSE AND WITHDRAWAL, EATING 
DISORDERS, AND CENTRAL NERVOUS 
SYSTEM DISEASES AND PATHOLOGIES 
CROSS-REFERENCED TO RELATED 
APPLICATIONS 
This application is a Divisional of application Ser. No. 
09/628,557 filed Jul. 28, 2000, now U.S. Pat. No. 6,455,543 
issued Sep. 24, 2002, which claims the benefit of Provisional 
Application No. 60/146,144 filed Jul. 30, 1999. 
FIELD OF THE INVENTION 
The present invention relates to lobeline analogs, specifi-
cally cis-2,6-disubstituted piperidines, and their method of 
use in the treatment of diseases and pathologies of the 
central nervous system (CNS), the treatment of drug abuse 
and withdrawal therefrom as well as to the treatment of 
eating disorders such as obesity. 
BACKGROUND OF THE INVENTION 
Alpha-Lobeline (lobeline), a lipophilic nonpyridino, alka-
loidal constituent of Indian tobacco, is a major alkaloid in a 
family of structurally-related compounds found in Lobelia 
inflata. Lobeline has been reported to have many nicotine 
like effects, including tachycardia and hypertension (Olin et 
al., 1995), hyperalgesia (Hamann et al., 1994) and improve-
ment of learning and memory (Decker et al., 1993). Lobeline 
has high affinity for nicotinic receptors (Lippiello et al., 
1986; Broussolle et al., 1989). However, no obvious struc-
tural resemblance of lobeline to nicotine is apparent and 
structure function relationships between S(-)-nicotine and 
lobeline do not suggest a common pharmacophore (Barlow 
et al., 1989). Also, differential effects of lobeline and nico-
tine suggest that these drugs may not be active through a 
common CNS mechanism, even though lobeline has been 
considered a mixed nicotinic agonist/antagonist. 
2 
The compound can be administered alone, combined with 
an excipient, co-administered with a second drug having a 
similar or synergistic effect. The compound is administered 
subcutaneously, intramuscularly, intravenously, 
5 transdermally, orally, intranasally, intrapulmonary or rec-
tally. The use of cis-2,6-disubstituted piperidines and deriva-
tives thereof in treating diseases or pathologies of the CNS 
is implicated. In particular, the treatment of dependencies of 
such drugs as cocaine, amphetamine, caffeine, nicotine, 
10 
phencyclidine, opiates, barbiturates, benzodiazepines, 
canabinoids, hallucinogens, and alcohol is implicated. Also, 
the treatment of eating disorders such as obesity is impli-
cated. 
In a preferred aspect of the invention, the method of 
15 
treatment reduces an individual's desire for the drug of 
abuse or for food by at least one day, but it is also preferred 
that the treatment method further comprise administering 
behavior modification counseling to the individual. 
Although the compound of the present invention is contem-
plated primarily for the treatment of drug abuse and with-
20 drawal and for eating disorders, other uses are also sug-
gested by the studies discussed herein. Thus, cognitive 
disorders, brain trauma, memory loss, psychosis, sleep 
disorders, obsessive compulsive disorders, panic disorders, 
myasthenia gravis, Parkinson's disease, Alzheimer's 
25 disease, schizophrenia, Tourette's syndrome, Huntington's 
disease, attention deficit disorder, hyperkinetic syndrome, 
chronic nervous exhaustion, narcolepsy, motion sickness 
and depression, and related conditions are considered to be 
susceptible to treatment with a compound of the present 
30 invention. 
As shown by the results of the studies described herein, 
lobeline analogs are found to be effective in inhibiting 
uptake of extracellular DA by cells of the CNS. Some of 
these analogs are also nicotinic receptor antagonists. Either 
35 or both mechanisms can thereby work to alter the distribu-
tion of the intracellular DA pools and as a result alter 
extracellular DA concentration. 
Lobeline evokes dopamine (DA) release from rat striatal 
slices. However, lobeline evoked DA release is neither 
dependent upon extracellular calcium nor is it sensitive to 40 
mecamylamine, a noncompetitive nicotinic receptor antago-
nist. Thus, lobeline evoked DA release occurs via a different 
mechanism than does nicotine to evoke DA release (Teng et 
al., 1997, 1998; Clarke et al., 1996). In this respect, lobeline 
also inhibits DA uptake into rat striatal synaptic vesicles via 45 
an interaction with the dihydrotetrabenazine (DTBZ) site on 
vesicular monoamine transporter-2 (VMAT2), thus increas-
ing the cytosolic DA available for reverse transport by the 
plasma membrane transporter (DA1) (Teng et al., 1997, 
1998). Thus, lobeline interacts with nicotinic receptors and 50 
blocks nicotine-evoked DA release, but also interacts with 
DA transporter proteins to modify the concentration of DA 
As used herein the term "lobeline" refers to a compound 
having the general chemical formula 2-[6-(~­
hydroxyphenethyl)-1-methyl-2-piperidy 1 ]-acetophenone. 
The term "lobeline analogs" and equivalents thereof as used 
herein, refers to chemical derivatives of lobeline obtained by 
oxidation or reduction of lobeline, others obtained by esteri-
fication of lobeline and redox derivatives, as well as various 
substitutions at the N-position of the piperidinyl moiety. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The 2,6-disubstituted piperidine lobeline analogs of the 
present invention include those contemplated by the follow-
ing formula (I), without regard to chirality: 
in the cytosolic and vesicular storage pools, thereby altering 
subsequent dopaminergic neurotransmission. 
SUMMARY OF THE INVENTION 
The present invention is directed to a method of treating 
55 
an individual who suffers from a disease or pathology of the 
central nervous system (CNS) or for treating an individual 
for drug dependence or withdrawal for drug dependence. 
The method comprises of administering to the individual an 60 
effective amount of a cis-2,6-substituted piperidino 
compound, i.e., a lobeline analog, including pharmaceuti-
cally acceptable salts of such compounds thereof. As used 
herein, an "effective amount" refers to an amount of a drug 
effective to reduce an individual's desire for a drug of abuse 65 
or for food, or for alleviating at least one of the symptoms 
of the disease or pathological symptom of a CNS pathology. 
(I) 
wherein: 
n is zero or an integer in the range from 1 to 3; 
X1- Y1 and X2 - Y2 are the same or are independently 
different from one another and represent a saturated carbon-
carbon bond, a cis-carbon-carbon double bond, a trans-
carbon-carbon double bond, a carbon-carbon triple bond; a 
US 6,943,177 B2 
3 
saturated sulfur-carbon bond, a saturated selenium-carbon 
bond, an oxygen-carbon bond, a saturated nitrogen-carbon 
bond, a N-alkyl substituted saturated nitrogen-carbon bond 
where said alkyl is a lower straight chain or branched alkyl, 
a nitrogen-carbon double bond, or a nitrogen-nitrogen 
double bond; 
R1 and R4 are the same or are independently different 
from one another and represent hydrogen or a lower straight 
chain or branched alkyl or R1 and R4 together form a ring 
including a -CH2-, -CH2CH2-, -CH2CH2-CH2-, 
-cis-CH=CH, -cis-CH2-CH=CH- or -cis-CH2=CH-
CH2- moiety; 
4 
to, thiazolidine, thiazole and oxazin, including all possible 
substitution patterns, geometric and stereoisomers, racemic, 
diastereomeric and enantiomeric forms thereof. 
The substituted benzene includes at least one substituent, 
5 where the substituent is selected from, but is not limited to, 
the group consisting of methyl, ethyl, propyl, isopropyl, 
butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-
dimethylamino, carboxylate, methylcarboxylate, 
ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, 
10 carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, 
cyano, aminomethyl, N -methylaminomethyl, N ,N-
dimethylaminomethyl, carboxamide, 
N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, 
propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, 
R2 and R3 are the same or are independently different 
from one another and represent a saturated or unsaturated 
hydrocarbon ring; a nitrogen containing heterocyclic moi-
ety; an oxygen containing heterocyclic moiety; a sulfur 
containing heterocyclic moiety; a selenium containing het-
erocyclic moiety; a mixed heterocyclic moiety containing at 
least two atoms selected from the group consisting of 
nitrogen, oxygen and sulfur; and an ortho, meta or para- 20 
substituted benzene; 
15 methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, 
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo, 
trifiuoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, 
ureido, azido, isocyanate, thioisocyanate, hydroxylamino 
and nitroso. 
It is preferred that when either X1- Y1 or X2- Y2 is a 
saturated carbon-carbon bond, Y1 or Y2 represents CH2, 
CH-OH, CHO-alkyl where said alkyl is a lower straight 
chain or branched alkyl, CH-OS02-C6H5 , CH-OS02-
p-C6H4CH3, CH-SH, C6H5-SH, CH-S-alkyl where said 
with the proviso that when n=O, R2 and R3 are unsubsti-
tuted phenyl groups, and X1-Y1 and X2-Y2 are saturated 
carbon-carbon bonds, Y1 cannot be CH2, CHOH or C=O, 
and Y2 cannot be CH2, CHOH, or C=O. 
It is preferred that when R2 and/or R3 is a saturated 
hydrocarbon ring, the ring includes, but is not limited to, 
cyclobutane, cyclopentane, cyclohexane, cycloheptane or 
cyclooctane, including all possible substitution patterns, 
geometric and stereoisomers, racemic, diastereomeric and 
enantiomeric forms thereof. 
It is further preferred that when R2 and/or R3 is an 
unsaturated hydrocarbon ring, the ring includes, but is not 
limited to, benzene, cyclopentene, cyclohexene, 
cycloheptene, cyclooctene or cyclopentadiene, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is further preferred that when R2 and/or R3 is a nitrogen 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, azetine, piperdine, piperazine, pyrazine, 
pyrazole, pyrazolidine, imidazole imidazoline, pyrimidine, 
hexa-hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-
triazole, 1,2,4-triazole, pyridine or pyridazine, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is further preferred that R2 and/or R3 is an oxygen 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, furan, tetrahydrofuran, 2,5-dihydrofuran, 
pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4-
oxathinin, including all possible substitution patterns, geo-
metric and stereoisomers, racemic, diastereomeric and enan-
tiomeric forms thereof. 
It is further preferred that when R2 and/or R3 is a sulfur 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, thietane, thiophene, thiophane, 2,5-
dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2-
dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-
dithane, 1,4-dithiane, or thiopyranylium, including all 
possible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
It is further preferred that when R 2 and/or R 3 is a selenium 
containing heterocyclic moiety, the moiety includes, but is 
not limited to, selenophene, including all possible substitu-
tion patterns, geometric and stereoisomers, racemic, diaste-
reomeric and enantiomeric forms thereof. 
It is further preferred that when R2 and/or R3 is a mixed 
heterocyclic moiety, the moiety includes, but is not limited 
25 alkyl is a lower straight chain or branched alkyl, CH-N02, 
CH-CF3, CH-NHOH, CH-OCHO, CH-F, CH-Cl, 
CH-Br, CH-I, CH-NH2, CH-NH-alkyl where said 
alkyl is a lower straight chain or branched alkyl, CH-N 
(alkyl)2 where said alkyl is a lower straight chain or 
30 branched alkyl, CH-OCONH2, CH-OCONH-alkyl 
where said alkyl is a lower straight chain or branched alkyl, 
CH-OCON(alkyl)2 where said alkyl is a lower straight 
chain or branched alkyl, CH-N3, C=O or C=S; CH-0-
aryl such as a phenyl, ortho-, meta-, or para-substituted 
35 phenyl where the substituent is as described above; or a 
hydrocarbon or hetercyclic ring such as pyridyl, furanyl, 
naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-triazole, 
1,2,4-triazole, imidazoline, pyrimidine, pyridazine or 
triazine, including all possible substitution patterns, diaste-
40 reomeric and enantiomeric forms thereof. 
The lower straight or branched alkyl can be an alkyl group 
containing one to seven carbon atoms. The preferred alkyl 
groups are methyl and ethyl. 
The above 2,6-substituted piperidino analogs are pre-
45 ferred in their cis-geometrical isomeric forms, or in their 
trans geometric forms, including all possible geometric, 
racemic, diasteriomeric, and enantiomeric forms thereof. 
The above cis-2,6-disubstituted piperidines as well as 
analogs thereof can be administered in their free base form 
50 or as a soluble salt. Whenever it is desired to employ a salt 
of a cis-2,6-substituted piperidine or its analog, it is pre-
ferred that a soluble salt be employed. Some preferred salts 
include hydrochloride, hydrobromide, nitrate, sulfate, 
phosphate, tartrate, galactarate, fumarate, citrate, maleate, 
55 glycolate, malate, ascorbate, lactate, aspartate, glutamate, 
methanesulfonate, p-toluenesulfonate, benzenesulfonate, 
salicylate, proprionate, and succinate salts. The above salt 
forms may be in some cases hydrates or solvates with 
alcohols and other solvents. 
60 A pharmaceutical composition containing a compound of 
the invention is also contemplated, which may include a 
conventional additive, such as a stabilizer, buffer, salt, 
preservative, filler, flavor enhancer and the like, as known to 
those skilled in the art. Representative buffers include 
65 phosphates, carbonates, citrates and the like. Exemplary 
preservatives include EDTA, EGTA, BHA, BHT and the 
like. A composition of the invention may be administered by 
US 6,943,177 B2 
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constants (Ki values) ranging from 0.0043 ,uM to >100 ,uM. 
Five of these compounds were in the range of 4--160 nM. 
Three of these compounds were in the range of 0.93-14 ,uM. 
One compound was >100 ,uM. The cis-2,6-disubstituted 
inhalation, i.e., intranasally as an aerosol or nasal formula-
tion; topically, i.e., in the form of an ointment, cream or 
lotion; orally, i.e., in solid or liquid form (tablet, gel cap, 
time release capsule, powder, solution, or suspension in 
aqueous or non aqueous liquid; intravenously as an infusion 
or injection, i.e., as a solution, suspension or emulsion in a 
pharmaceutically acceptable carrier; transdermally, e.g., via 
a transdermal patch; rectally as a suppository and the like. 
5 piperidino derivatives listed in Table 1 were also assayed for 
inhibition of DAT activity, i.e., inhibition of [3 H]DA uptake 
into the dopaminergic presynaptic terminal. Nine com-
pounds were evaluated and afforded inhibition constants (Ki Generally, the pharmacologically effective dose of a 
present compound is in the amount ranging from about 
1x10-5 to about 1 mg/kg body weight/day. The amount to be 10 
administered depends to some extent on the lipophilicity of 
the specific compound selected, since it is expected that this 
property of the compound will cause it to partition into fat 
deposits of the subject. The precise amount to be adminis-
tered can be determined by the skilled practitioner in view 15 
of desired dosages, side effects and medical history of the 
patient and the like. 
The cis-2,6-disubstituted piperidino analogs of the present 
invention exhibit selectivity for either neuronal nicotinic 
acetylcholine receptors and/or the dopamine transporter 20 
protein (DAT). The derivatives that are active towards the 
nicotinic receptor generally do not interact with the DAT, 
and those that interact with the DAT show only modest 
nicotinic receptor activity. 
values) ranging from 0.08 ,uM to 54 ,uM. 
Removal of both functionalities of the lobeline molecule 
resulted in loss of affinity for the nicotinic receptor and a 
100-fold more potent inhibition of the dopamine transporter 
compared with lobeline. Removal of either the hydroxyl 
group or the keto group of lobeline resulted in a 50-fold loss 
of affinity for the nicotinic receptor. Interestingly, the 
ketoalkene analog inhibited DAT 10-fold more potently than 
lobeline, whereas lobelanidine inhibited DAT equipotently 
compared to lobeline. Conversion of the hydroxy group of 
lobeline to a bulky tosyloxy group reduced the affinity of the 
nicotinic receptor by only 3-fold, but did not alter the 
interaction with the DA transporter. The hydroxyalkene had 
a similar potency with the meso-transdiene (the most potent 
compound) in the DA uptake assay, but had 1000-fold lower 
affinity for the nicotinic receptor. Also, the completely 
TABLE 1 
(II) 
25 defunctionalized lobeline molecule and the hydroxyalkane 
analog were both less potent than the meso-transdiene in 
inhibiting DA uptake into striatal synaptosomes. This data 
indicates that appropriate structural modification of the 
lobeline molecule affords compounds in which the interac-
30 tion with DAT is enhanced. Furthermore, in one compound, 
i.e., the meso-transdiene, the nicotinic receptor interaction 
has been eliminated and the compound is thus selective for 
inhibition of DAT. 
Ki (uM) 
[3H]-Nicotine 
Compound Binding Assay 
1. X 1 ~ X2 ~ CH2 0.0043 
Y' ~ c~o 
Y2 ~ (S)---CHOH 
2. X 1 ~ X2 ~ Y 1 ~ Y2 ~ CH2 14.3 
3. X 1 ~ X2 ~ CH2 0.0041 
Y' ~ c~o 
Y2 ~ (S)---CHOS02---C6 H4-p-CH3 
4. X 1 ~ X2 ~ CH2 11 
Y' ~Y2 ~ c~o 
5. X', Y 1 ~ X2, Y2 ~ trans CH~CH >100 
6. X 1 ~ CH2 0.13 
Y' ~ c~o 
X2, Y2 ~ trans CH~CH 
7. X 1 ~ X2 ~ CH2 0.93 
Y 1 ~ (S)---CHOH 
Y2 ~ (R)---CHOH 
8. X 1 ~ X2 ~ Y2 ~ CH2 0.16 
Y 1 ~ (RS)---CHOH 
9. X 1 ~ CH2 4.2 
Y 1 ~ (S)---CHOH 
X2, Y2 ~ trans CH~CH 
Ki (uM) 
[3H]-Dopamine 
Uptake Assay 
45 
3.0 
39 
25 
0.8 
3.0 
54 
8.9 
1.3 
35 
40 
45 
50 
55 
The invention will now be discussed by certain examples 
that illustrate but do not limit the invention. 
EXAMPLE 1 
Cis-2, 6 -di-trans-styry !piperidine 
1.00 g (2.95 mmol) oflobelanidine was dissolved in 15 ml 
of 85% H3 P04 and allowed to stir overnight at 60° C. The 
reaction mixture was taken up in H2 0 and made basic with 
solid K2 C03 (pH-8). The pH was adjusted by the addition 
of solid NaOH (pH-10). The aqueous solution was extracted 
three times with 15 ml of EtOAc. The organic layers were 
combined and dried over anhydrous MgS04 . The salts were 
removed via filtration and solvent removed by rotary evapo-
ration affording 0.70 g of crude product. This compound was 
recrystallized from MeOH affording 0.60 g of pure cis-2,6-
di-trans-styrylpiperidine. Percent yield=78.6% 
Mp=139-141 o C. 1 H NMR (300 MHz, CDC13) d: 1.40-1.80 
(m, 6H), 2.23 (s, 3H), 2.50--2.64 (t, 2H), 6.04-6.20 (dd, 2H), 
6.39-6.50 (d, 2H) and 7.10-7.38 (m, 10H); 13C NMR 
(CDC13) d: 23.75, 33.56, 42.32, 68.36, 126.26, 127.38, 
128.61, 130.52, 133.89 and 137.13 ppm. 
EXAMPLE 2 
Cis-2S,6R,8S-2-[ 6-~-para­
toluenesulfonyloxyphenethyl)-1-methyl-2-
piperidyl]-acetophenone 
The nine cis-2,6-disubstituted piperidino derivatives 
listed in Table 1 have the chemical structure of formula (II). 
They were assayed for nicotinic receptor interaction and 
inhibition of DAT activity. The cis-2,6-disubstituted piperi-
dino analogs of the present invention exhibit selectivity for 60 
either neuronal nicotinic acetylcholine receptors and/or the 
dopamine transporter protein (DAT). The derivatives that 
are active towards the nicotinic receptor generally do not 
interact with the DAT, and those that interact with the DAT 
show only modest nicotinic receptor activity. 
1.00 g (2.58 mmol) of lobeline hemisulfate was dissolved 
in 25 ml of pyridine and was added dropwise to a solution 
(cooled to 0° C.) containing 0.60 g (3.14 mmol) of 
65 p-toluenesulfonyl chloride dissolved in 15 ml of pyridine. 
The nine compounds in Table 1 were evaluated in the high 
affinity [3 H]nicotine binding assay and afforded inhibition 
After addition, the reaction was allowed to stir for 2 hours 
and then poured into 50 ml of ice-cold water and the mixture 
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was stirred for an additional two hours. The aqueous solu-
tion was extracted three times with 25 ml of EtOAc. The 
organic layers were combined and dried over anhydrous 
Na2S04 . The salts were removed by filtration and the 
solvent was removed by rotary evaporation affording 450 5 
mg of a pink-colored compound. The product was recrys-
tallized from acetone yielding 300 mg of the product. 
Percent yield=21.6% mp=169.1-171.0° C. 1H NMR (300 
MHz, CDC13) ll: 1.30-1.98 (m, 6H), 2.20 (s, 3H), 2.63-2.74 
and placed into a Parr hydrogenation apparatus with 0.10 g 
of 10% Pd-on-Carbon. After removal of air, hydrogen gas 
was introduced until a pressure of 40 psig was reached. The 
reaction was allowed to proceed for 48 hrs. The Pd catalyst 
was removed through filtration with Celite, and ethanol was 
removed by rotary evaporation to afford 0.30 g of a yellow 
oil. The compound was purified by silica gel chromatogra-
phy eluting with EtOAc to afford 0.25 g of the product. The 
yield was 50.0%. 1H NMR (300 MHz, CDC13) ll: 0.70-0.90 
(m, 6H), 1.18 (s, 3H), 1.40-1.90 (m, 6H), 2.44-2.56 (m, 
2H), 4.56-4.60 (dd, lH) and 7.04-7.30 (m, 10H); 13C NMR 
(CDC13) ll: 25.77, 29.24, 29.38, 29.42, 29.46, 29.68, 31.44, 
35.93, 39.07, 74.64, 125.50, 125.85, 127.42, 128.17, 128.35, 
128.37, 142.85 and 144.91 ppm. 
(d, 3H), 2.95-3.20 (m, 2H), 3.61-3.78 (d, lH), 3.83-4.12 10 
(m, 2H), 4.50-4.72 (m, lH), 4.80-4.90 (d, lH), 6.90-7.00 
(d, 2H), 7.10-7.50 (m, 8H), 7.50-7.60 (d, 2H), 7.80--7.90 (d, 
2H) and 9.85 (s, lH); 13C NMR (CDC13 ) ll: 21.16, 22.25, 
23.32, 23.55, 27.35, 38.29, 40.18, 40.07, 60.79, 63.69, 
71.05, 125.56, 125.76, 127.39, 128.28, 128.44, 128.69, 15 
128.77, 133.67, 133.96, 135.87, 140.03, 141.98, 144.47 and 
195.21 ppm. 
EXAMPLE 6 
High Affinity [3 H]Nicotine Binding Assay 
EXAMPLE 3 
Cis-2S,6R-N-methyl-6-phenacyl-2-trans-
styrylpiperidine 
1.00 g (2.58 mmol) of lobeline hemisulfate was dissolved 
in 15 ml of 85% H3P04 and the solution was allowed to stir 
for 24 hrs at 50° C. Phosphoric acid was then neutralized 
with K2 C03 , and a little ice cold H2 0 was added to dissolve 
the salts. The aqueous solution was extracted with ethyl 
acetate (20 mlx3). The organic layers were combined and 
dried with anhydrous MgS04 . The salts were removed by 
filtration and the solvent was removed via rotary 
evaporation, affording 0.80 g of a gummy solid, which 
contained mainly the trans isomer. Percent yield=84.6%. 1H 
NMR (300 MHz, CDC13) 1.15-1.60 (m, 6H), 2.02 (s, 3H), 
2.47-2.71 (m, 3H), 3.16-3.34 (dd, lH), 5.80-6.00 (dd, lH), 
6.18-6.28 (d, lH), and 6.90--7.38 (m, 8H) and 7.64--7.80 (d, 
2H); 13C NMR (CDC13) 23.52, 32.56, 33.17, 40.52, 44.02, 
59.62, 68.08, 126.00, 127.15, 127.92, 128.36, 128.44, 
130.29, 132.91, 133.91, 136.95, 136.99 and 198.83 ppm. 
EXAMPLE 4 
Cis-10R,2S,6R- and Cis-10S,2S,6R-N-methyl-6-[1-
(2-hydroxy-2-pheny 1)-ethyl ]-2-trans-styry !piperidine 
In a 250 ml round bottom flask was added 0.80 g of 
cis-2S,6 R-N-meth y 1-6-p he nacy 1-2-trans-s tyry lpipe ridine, 
and 50 ml of ethanol. Sodium borohydride was added until 
all of the starting material was consumed (determined by 
TLC). The solution was cooled to 0° C. and acetone was 
added in small portions to quench the reaction. The solvents 
were evaporated to dryness and water was added precipi-
tating 0.75 g of an off-white crystalline solid (1:1) mixture 
The ability to displace S(-)[3H]NIC binding from rat 
20 striatal membranes to assess interaction with the a4~2 
subtype was determined. The [3H]NIC binding assay was 
performed according to previously published methods 
(Romano et al., 1980; Marks et al., 1986; Crooks et al., 
1995). Striata from two rats were dissected, pooled and 
25 homogenized with a Tekmar polytron in 10 vol of ice-cold 
modified Krebs-HEPES buffer (in mM; 20 HEPES, 118 
NaCl, 4.8 KCl, 2.5 CaC12 , 1.2 MgS04 , adjusted to pH to 
7.5). The homogenate was incubated at 37° C. for 5 minutes 
to promote hydrolysis of endogenous acetylcholine, and 
30 centrifuged at 15,000 g for 20 minutes and the pellet was 
resuspended in 10 vol of ice-cold distilled water and incu-
bated at 37° C. for 5 minutes, followed by centrifugation at 
15,000 g for 20 min. The pellet containing the striatal 
membranes was resuspended in 10 vol of fresh ice-cold 10% 
35 Krebs-HEPES buffer and incubated at 37° C. for 10 min 
after which it was centrifuged at 15,000 g for 20 minutes. 
The lafter sequence of resuspension, incubation and cen-
trifugation was repeated. The pellet was frozen under fresh 
Krebs-HEPES buffer and stored at -40° C. until assay. Upon 
40 assay, the pellet was resuspended in Krebs-HEPES buffer, 
incubated at 37° C. for 5 minutes and centrifuged at 15,000 
g for 20 min. The final pellet was resuspended in 3.6 ml 
ice-cold water which provides for approximately 200 jAg 
protein/100 tAl aliquot. Competition assays were performed 
45 in duplicate in a final volume of 200 tAl Krebs-HEPES buffer 
containing 250 mM Tris buffer (pH 7.5 at 4° C.). Reactions 
were initiated by addition of 100 tAl of membrane suspension 
to 3 nM [3 H]NIC (50 tAl) and 1 of at least 9 concentrations 
of analog (50 tAl). After 90 minutes incubation at 4° C., 
50 reactions were terminated by dilution of the samples with 3 
ml of ice-cold buffer followed immediately by filtration 
through a Whatman GF/B glass fiber filters (presoaked in 
0.5% polyethyleneimine (PEl) using a Brandel Cell Har-
vester. Filters were rinsed 3x with 3 ml of ice-cold buffer, 
of diastereomers, which was purified on silica eluting with 
75:25 (CHCl3/EtOH). The yield of the product (a mixture of 
diastereomers) was 93.4%. 1H NMR (300 MHz, CDC13 ) ll: 
1.17-2.06 (m, 12H), 2.12 (s, 3H), 2.35 (s, 3H), 2.50-6.20 
(m, 4H), 2.70--3.20 (m, 4H), 4.78-4.80 (dd, lH), 5.04-5.14 
(dd, lH), 5.96-6.20 (m, 2H), 6.32-6.42 (dd, 2H) and 
7.04-7.34 (m, 20H); 13C NMR (CDC13 ) ll: 23.69, 24.15, 
26.74, 29.68, 33.26, 39.94, 41.10, 41.41, 62.93, 63.00, 
65.62, 68.32, 71.76, 73.90, 125.46, 126.15, 126.19, 126.83, 
127.01, 127.37, 128.16, 128.23, 128.50, 130.58, 132.61, 60 
133.85, 136.83, 136.95, 145.32 and 145.45 ppm. 
55 transferred to scintillation vials and 5 ml scintillation cock-
tail added. Nonspecific binding was defined as binding in the 
presence of 10 jAM NIC. For competition curves, the IC50 
values were corrected for ligand concentration (Cheng et al., 
1973). 
EXAMPLE 7 
EXAMPLE 5 
Cis-2S,6R-N -methyl-6-[1-(2-hydroxy-2-phenyl) 
ethy 1 ]-2-pheny lethy !piperidine 
0.50 g (1.55 mmol) of cis-2S,6R-N-methyl-6-phenacyl-
2-trans-styrylpiperidine was dissolved in 50 ml of ethanol 
65 
[ 3 H]Dopamine ([3H]DA) Uptake Assay, Striatal 
Synaptosomal Preparation 
[ 3H]DA uptake was performed according to a modifica-
tion of the previously reported methods (Dwoskin et al., 
1999). Striata were homogenized in 20 ml of ice-cold 
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construction and operation shown and described, and 
accordingly, all suitable modifications and equivalence 
thereof may be resorted to, falling within the scope of the 
invention claimed. 
REFERENCES 
sucrose solution (0.32 M sucrose and 5 mM sodium 
bicarbonate, pH 7.4) with 12 passes of a teflon-pestle 
homogenizer (clearance approximately 0.003 in). The 
homogenate was centrifuged at 2,000 g, 4° C. for 10 min. 
The supernatant was centrifuged at 12,000 g, 4° C. for 20 5 
minutes. The resulting pellet was resuspended in 1.5 ml 
ice-cold assay buffer (in mM; 125 NaCl, 5 KCl, 1.5 
KH 2 P0 4 , 1.5 MgS0 4 , 1.25 CaC12 , 10 glucose, 0.1 
L-ascorbate, 25 HEPES, 0.1 EDTA and 0.1 pargyline; pH 
7.4). The final protein concentration was 400 ,ug/ml. Assays 
were performed in duplicate in a total vol of 500 ,ul. Aliquots 
(50 ,ul synaptosomal suspension containing 20 ,ug of protein) 
were added to assay tubes containing 350 ,ul buffer and 50 
The pertinent disclosures of the references listed below 
and as discussed above herein are incorporated herein by 
10 reference. 
,ul of 1 of 9 concentrations (final concentration, 1 nM-1 mM) 15 
of analog or vehicle. Synaptosomes were preincubated at 
34 o C. for 10 min before the addition of 50 ,ul of [3 H]DA 
(30.1 Ci/mmole, final concentration 10 nM) and accumula-
tion proceeded for 10 min at 34 o C. High affinity uptake was 20 
defined as the difference between accumulation in the 
absence and presence of 10 ,uM GBR 12935. Preliminary 
studies demonstrated that at 10 minutes [3 H]DA uptake is 
within the linear range of the time-response curve when 
experiments are performed at 34° C. Accumulation was 25 
terminated by addition of 3 ml ice-cold assay buffer con-
taining 1 mM pyrocatechol and rapid filtration through a 
Whatman GF/B glass fiber filter paper (presoaked with 
buffer containing 1 mM pyrocatecol) using a Brandel Cell 
Harvester. The filters were washed 3 times with 3 ml of 10 30 
ml ice-cold buffer containing 2 mM pyrocatechol, and then 
transferred to scintillation vials and radioactivity determined 
(Packard Model B1600TR scintillation counter, Meriden, 
Conn.). Protein concentration was determined using bovine 
35 
serum albumin as the standard (Bradford, 1976). Competi-
tion curves for analog inhibition of [3 H]DA uptake were 
generated. Nonlinear regression analysis was used to fit 
curves either in the absence or presence of 9 concentrations 
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new class of nicotinic antagonist," Drug Dev. Res., 1995; 36: 
71-82. 
Decker M. W. et al., "Effects of lobeline, a nicotinic 
receptor agonist, on learning and memory," Pharmacal. 
Biochem. Behav. 1993; 45: 571-576. 
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calcium-dependent manner," J. Pharmacal. Exp. Therap., 
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of analog. IC50 values were corrected for concentration of 40 
[ 3H]DA (Cheng-Prusoff, 1973) to yield true inhibition con-
stants (Ki=IC50/[1+c/Km]), where cis the concentration of 
free [3 H]DA and Km is the concentration of analog at which 
half maximal [3 H]DA uptake is achieved. These values (Ki) 
were converted to pKi before statistical analysis. 
Hamann S. R. et al., "Hyperalgesic and analgesic actions 
of morphine, U50-488, naltrexone, and (-)lobeline in the rat 
brainstem," Pharmacal. Biochem. Behav., 1994; 47: 
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In the examples listed in the Table, a series of cis-2,6-
disubstituted piperidines, structurally related to lobeline, 
were synthesized and tested for activity in the high affinity 
nicotinic receptor binding assay and the dopamine uptake 50 
assay to assess the interaction of these piperidines with these 
specific proteins on the presynaptic terminal of dopaminer-
gic neurons in the CNS. Some of these compounds have 
greater selectivity for interaction with DAT than for inter-
action with nicotinic receptors, whereas other compounds 
interact with both nicotinic receptors and DAT, more similar 
Olin B. R. et al., Drug Facts and Comparisons, 1 B 
55 
Lippincott Co., St. Louis, Mo., pp 3087-3095 (1995). 
to lobeline. Other compounds were more selective for the 
nicotinic receptor than for DAT. These combinations of 
pharmacological activity are considered to be beneficical for 
the treatment of psychostimulant abuse and withdrawal, 60 
eating disorders, and central nervous system diseases and 
pathologies. 
The foregoing is considered as illustrative only of the 
principles of the invention. Further, since numerous modi- 65 
fications and changes will readily occur to those skilled in 
the art, it is not desired to limit the invention to the exact 
Romano C. et al., "Stereospecific nicotinic receptors on 
rat brain membranes," Science, 1980; 210: 647-650. 
Teng L. H. et al., "Lobeline and nicotine evoke [3H]-
overfiow from rat striatal slices preloaded with [3 H] 
dopamine: differential inhibition of synaptosomal and 
vesicular [3 H]dopamine uptake," J. Pharmacal. Exp. 
Therap., 1997; 80: 1432-1444. 
Teng L. H. et al, "Lobeline displaces [ 3 H] 
dihydrotetrabenazine binding and releases [3H]dopamine 
from rat sriatal synaptic vesicles," J. Neurochem., 1998; 71: 
258-265. 
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What is claimed is: 
1. A method of treating an individual for dependence on 
a drug of abuse or withdrawal from a drug of abuse 
comprising administering to the individual an effective 
amount of a cis-2,6-substituted piperidino compound or 5 
pharmaceutically effective salt thereof comprising formula 
(I): 
(I) 
10 
15 
12 
straight chain or branched alkyl, C3-C6 cycloalkyl, 
vinyl, allyl, C4-C7 alkenyl, benzyl, phenylethyl, 
N-methylamino, N,N-dimethylamino, carboxylate, 
me th ylc arb o xyl ate, e th ylc arb o xyla te, 
propylc arb oxyla te, isop ropylc arb oxyla te, 
carboxaldehyde, acetoxy, propionyloxy, 
isopropionyloxy, cyano, aminomethyl, 
N -methylaminomethy 1, N ,N -dimethylaminomethyl, 
carboxamide, N-methylcarboxamide, N,N-
dimethylcarboxamide, acetyl, propionyl, formyl, 
benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, 
ethoxy, propoxy, isopropoxy, thiol, methylthio, 
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo, 
trifiuoromethyl, propargyl, nitro, carbamoyl, ureido, 
azido, isocyanate, thioisocyanate, hydroxylamino, and 
nitroso. 
wherein: 
X1-Y1 and X2-Y2 are the same or are independently 
different from one another and represent a saturated 
carbon-carbon bond, a cis-carbon-carbon double bond, 
2. The method of claim 1, wherein said drug of abuse is 
selected from the group consisting of cocaine, amphetamine, 
caffeine, nicotine, phencyclidine, opiates, barbiturates, 
20 benzodiazepines, canabinoids, hallucinogens, and alcohol. 
3. The method of claim 1, wherein said administering of 
the compounds is performed subcutaneously, 
intramuscularly, intravenously, transdermally, orally, 
intranasally, intrapulmonary or rectally. 
4. The method of claim 1, wherein said administering of 
the compound inhibits uptake of dopamine by cells of the 
central nervous system of the individual. 
a trans-carbon-carbon double bond, a carbon-carbon 
triple bond; a saturated sulfur-carbon bond, a saturated 
selenium-carbon bond, an oxygen-carbon bond, a satu- 25 
rated nitrogen-carbon bond, aN-alkyl substituted satu-
rated nitrogen-carbon bond where said alkyl is a lower 
straight chain or branched alkyl, a nitrogen-carbon 
double bond, or a nitrogen-nitrogen double bond; 
5. The method of claim 1, wherein said administering of 
the compound inhibits binding of neurotransmitters or drugs 
30 to nicotinic receptors on cells of the central nervous system 
of the individual. 
R1 and R4 are the same or are independently different 
from one another and represent hydrogen or a lower 
straight chain or branched alkyl or R1 and R4 together 
form a ring including a -CH2-, -CH2 CH2-, 
-CH2 CH2 -CH2-, -cis-CH=CH, -cis-CH2 -
CH=CH- or -cis-CH2=CH-CH2- moiety; and 
R2 and R3 are the same or are independently different 
from one another and represent a saturated or unsatur-
ated hydrocarbon ring; a nitrogen containing heterocy-
clic moiety; an oxygen containing heterocyclic moiety; 
35 
a sulfur containing heterocyclic moiety; a selenium 40 
containing heterocyclic moiety; a mixed heterocyclic 
moiety containing at least two atoms selected from the 
group consisting of nitrogen, oxygen and sulfur; and an 
ortho, meta or para-substituted benzene; 
with the proviso that when R2 and R3 are unsubstituted 45 
phenyl groups and X1 - Y1 and X2 - Y2 are saturated 
carbon-carbon bonds, Y1 and Y2 cannot be CHOR or 
C=O, wherein R is hydrogen, lower alkyl, lower 
alkenyl, lower alkylcarbonyl, arylcarbonyl, 
aralkylcarbonyl, lower alkoxycarbonyl, lower 50 
alkylamino-carbonyl, higher alkylcarbonyl or poly 
( alkyleneoxide )-carbonyl; 
with the further proviso that when R2 and R3 are unsub-
stituted phenyl groups or substituted phenyl groups 55 
having an alkyl, alkoxy, chlorine or CF3 as substituents 
and X1-Y1 and X2-Y2 are saturated nitrogen-carbon 
bonds, X1 and X2 cannot be C=O; and 
with the further proviso that when X1-Y1 and X2-Y2 
are saturated carbon-carbon bonds, X1 and X2 cannot 60 
be CH2 or CH=CH, and Y1 and Y2 cannot be CH2 or 
CH=CH, C=O or CHOH; 
6. The method of claim 1, wherein the saturated hydro-
carbon ring includes cyclobutane, cyclopentane, 
cyclohexane, cycloheptane or cyclooctane. 
7. The method of claim 1, wherein the unsaturated hydro-
carbon ring includes benzene, cyclopentene, cyclohexene, 
cycloheptene, cyclooctene or cyclopentadiene. 
8. The method of claim 1, wherein the nitrogen containing 
heterocyclic moiety includes azetine, piperidine, piperazine, 
pyrazine, pyrazole, pyrazolidine, imidazole imidazoline, 
pyrimidine, hexa-hydropyrimidine, pyrrole, pyrrolidine, 
triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or 
pyridazine. 
9. The method of claim 1, wherein the oxygen containing 
heterocyclic moiety includes furan, tetrahydrofuran, 2,5-
dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-
dioxane or 1,4-oxathinin. 
10. The method of claim 1, wherein the unsaturated sulfur 
containing heterocyclic moiety includes thietane, thiophene, 
thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3-
dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2-
dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium. 
11. The method of claim 1, wherein the selenium con-
taining heterocyclic moiety is selenophene. 
12. The method of claim 1, wherein the mixed heterocy-
clic moiety is thiazolidine, thiazole or oxazin. 
13. The method of claim 1, wherein the substituted 
benzene includes at least one substituent selected from the 
group consisting of methyl, ethyl, propyl, isopropyl, butyl, 
sec-butyl, isobutyl, amino, N-methylamino, N,N-
dimethylamino, carboxylate, methylcarboxylate, 
ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, 
carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, 
cyano, aminomethyl, N -methylaminomethyl, N ,N-
with the further proviso that when X1-Y1 and X2-Y2 
are carbon-carbon double bonds, R2 and R3 cannot be 
a saturated or unsaturated hydrocarbon ring with an 
ortho-, meta- or para substituted moiety selected from 
the group consisting of hydrogen, methyl, ethyl, C3-C7 
65 d i m e t h y 1 a m i n o m e t h y 1 , c a r b o x a m i d e , 
N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, 
propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, 
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chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl, 
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, 
hydroxylamino, and nitroso; or a hydrocarbon or heterocy-
clic ring comprising pyridyl, furanyl, naphthyl, thiazole, 
methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, 
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo, 
trifiuoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, 
ureido, azido, isocyanate, thioisocyanate, hydroxylamino 
and nitroso. 5 selenothenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole, 
imidazoline, pyrimidine, pyridazine or triazine. 14. The method of claim 1, wherein the saturated hydro-
carbon ring includes cyclobutane, cyclopentane, 
cyclohexane, cycloheptane or cyclooctane; the unsaturated 
hydrocarbon ring includes benzene, cyclopentene, 
cyclohexene, cycloheptene, cyclooctene or cyclopentadiene; 10 
the nitrogen containing heterocyclic moiety includes 
azetine, piperdine, piperazine, pyrazine, pyrazole, 
pyrazolidine, imidazole imidazoline, pyrimidine, hexa-
hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-
triazole, 1,2,4-triazole, pyridine or pyridazine; the oxygen 15 
containing heterocyclic moiety includes furan, 
tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 
1,4-dioxane, 1,3-dioxane or 1,4-oxathinin; the sulfur con-
taining heterocyclic moiety includes thietane, thiophene, 
thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3-
dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2-
dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium; the 
selenium containing heterocyclic moiety includes sele-
nophene; the mixed heterocycic moiety includes 
thiazolidine, thiazole or oxazin; and the substituent for the 
substituted benzene includes at least one member selected 
from the group consisting of methyl, ethyl, propyl, 
isopropyl, butyl, sec-butyl, isobutyl, amino, 
16. The method of claim 1, wherein the pharmaceutical 
salts are hydrochloride, hydro bromide, sulfate, hydrosulfate, 
citrate, fumarate and tartrate salts of said compound. 
17. The method of claim 15, wherein the pharmaceutical 
salts are hydrochloride, hydro bromide, sulfate, hydrosulfate, 
citrate, fumarate and tartrate salts of said compound. 
18. The method of claim 1, wherein said lower straight 
chain or branched alkyl contains one to seven carbon atoms. 
19. The method of claim 18, wherein said alkyl is methyl 
or ethyl. 
20. The method of claim 15, wherein said lower straight 
chain or branched alkyl contains one to seven carbon atoms. 
21. The method of claim 20, wherein said alkyl is methyl 
20 or ethyl. 
22. The method of claim 1, wherein said compound is 
cis-2S,6R,8S-2-[ 6-~-para -toluenesulfonyloxyphenethyl)-1-
methyl-2-piperidyl]-acetophenone. 
23. The method of claim 1, wherein said compound is 
25 cis-2S,6R-N -me thy 1-6-[1-(2-hydroxy-2-phenyl)ethyl ]-2-
phenylethylpiperidine. 
N -methylamino, N,N -dimethylamino, carboxylate, 
methylcarboxylate, ethylcarboxylate, propylcarboxylate, 30 
isopropylcarboxylate, carboxaldehyde, acetoxy, 
propionyloxy, isopropionyloxy, cyano, aminomethyl, 
N -methylaminomethyl, N ,N -dimethylaminomethyl, 
carboxainide, N -methylcarboxamide, N ,N-
dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, 35 
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, 
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro, 
chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl, 
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, 
hydroxylamino, and nitroso. 40 
15. The method of claim 1, wherein when either X1-Y1 
or X2-Y2 is a saturated carbon-carbon bond, Y1 or Y2 
represents CH2 , CH-OH, CHO-alkyl where said alkyl is a 
lower straight chain or branched alkyl, CH-OS02-C6H5 , 
CH-OS02 -p-C6H4 CH3 , CH-SH, C6H5-SH, CH-S- 45 
alkyl where said alkyl is a lower straight chain or branched 
alkyl, CH-N02 , CH-CF3 , CH-NHOH, CH-OCHO, 
CH-F, CH-Cl, CH-Br, CH-I, CH-NH2 , CH-NH-
alkyl where said alkyl is a lower straight chain or branched 
alkyl, CH-N(alkyl)2 alkyl where said alkyl is a lower 50 
straight chain or branched alkyl, CH-OCONH2 , 
CH-OCONH-alkyl where said alkyl is a lower straight 
chain or branched alkyl, CH-OCON(alkyl)2 where said 
alkyl is a lower straight chain or branched alkyl, CH-N3 , 
C=O or C=S; CH-0-phenyl, substituted CH-0- phe- 55 
nyl where the substituent is at least one member selected 
from the group consisting of methyl, ethyl, propyl, 
isopropyl, butyl, sec-butyl, isobutyl, amino, 
N -methylamino, N,N -dimethylamino, carboxylate, 
methylcarboxylate, ethylcarboxylate, propylcarboxylate, 60 
isopropylcarboxylate, carboxaldehyde, acetoxy, 
propionyloxy, isopropionyloxy, cyano, aminomethyl, 
N -methylaminomethyl, N ,N -dimethylaminomethyl, 
carboxamide, N-methylcarboxamide, N,N-
dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, 65 
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, 
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro, 
24. A cis-2,6-substituted piperidino compound or phar-
maceutically effective salt thereof comprising formula (I): 
(I) 
wherein: 
X1 - Y1 and X2 - Y2 are the same or are independently 
different from one another and represent a saturated 
carbon-carbon bond, a cis-carbon-carbon double bond, 
a trans-carbon-carbon double bond, a carbon-carbon 
triple bond; a saturated sulfur-carbon bond, a saturated 
selenium-carbon bond, an oxygen-carbon bond, a satu-
rated nitrogen-carbon bond, aN-alkyl substituted satu-
rated nitrogen-carbon bond where said alkyl is a lower 
straight chain or branched alkyl, a nitrogen-carbon 
double bond, or a nitrogen-nitrogen double bond; 
R1 and R4 are the same or are independently different 
from one another and represent hydrogen or a lower 
straight chain or branched alkyl or R1 and R4 together 
form a ring including a -CH2-, -CH2 CH2-, 
-CH2 CH2 -CH2-, -cis-CH=CH, -cis-CH2 -
CH=CH- or -cis-CH2=CH-CH2 - moiety; and 
R2 and R3 are the same or are independently different 
from one another and represent a saturated or unsatur-
ated hydrocarbon ring; a nitrogen containing heterocy-
clic moiety; an oxygen containing heterocyclic moiety; 
a sulfur containing heterocyclic moiety; a selenium 
containing heterocyclic moiety; a mixed heterocyclic 
moiety containing at least two atoms selected from the 
group consisting of nitrogen, oxygen and sulfur; and an 
ortho, meta or para-substituted benzene; 
with the proviso that when R2 and R3 are unsubstituted 
phenyl groups and X1-Y1 and X2-Y2 are saturated 
US 6,943,177 B2 
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carbon-carbon bonds, Y1 and Y2 cannot be CHOR or 
C=O, wherein R is hydrogen, lower alkyl, lower 
alkenyl, lower alkylcarbonyl, arylcarbonyl, 
aralkylcarbonyl, lower alkoxycarbonyl, lower 
alkylamino-carbonyl, higher alkylcarbonyl or poly 5 
( alkyleneoxide )-carbonyl; 
with the further proviso that when R2 and R3 are unsub-
stituted phenyl groups or substituted phenyl groups 
having an alkyl, alkoxy, chlorine or CF3 as substituents 
and X1 - Y1 and X2- Y2 are saturated nitrogen-carbon 10 
bonds, X1 and X2 cannot be C=O; and 
with the further proviso that when X1- Y1 and X2- Y2 
are saturated carbon-carbon bonds, X1 and X2 cannot 
be CH2 or CH=CH, and Y1 and Y2 cannot be CH2 or 
CH=CH, C=O or CHOH; 
with the further proviso that when X1-Y1 and X2-Y2 
are carbon-carbon double bonds, R2 and R3 cannot be 
15 
a saturated or unsaturated hydrocarbon ring with an 
ortho-, meta- or para substituted moiety selected from 
the group consisting of hydrogen, methyl, ethyl, C3-C7 20 
straight chain or branched alkyl, C3-C6 cycloalkyl, 
vinyl, allyl, C4 -C7 alkenyl, benzyl, phenylethyl, 
N-methylamino, N,N-dimethylamino, carboxylate, 
me th ylc arb oxyl ate, e th ylc arb o xyl ate, 
p ropylc arb oxyla te, isop ropylcarb oxyla te, 25 
carboxaldehyde, acetoxy, propionyloxy, 
isopropionyloxy, cyano, aminomethyl, 
N-methylaminomethyl, N,N-dimethylaminomethyl, 
carboxamide, N -methylcarboxamide, N ,N-
dimethylcarboxamide, acetyl, propionyl, formyl, 30 
benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, 
ethoxy, propoxy, isopropoxy, thiol, methylthio, 
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo, 
trifiuoromethyl, propargyl, nitro, carbamoyl, ureido, 
azido, isocyanate, thioisocyanate, hydroxylamino, and 35 
nitroso; and with the further proviso that R2 and R3 do 
not represent N,N'-bis(2,3,5,6,8,9,11,12-octahydro-1,4, 
7,1 0, 13-benzopentaoxacyclopentadecin -15-yl). 
25. The compound of claim 24, wherein the saturated 
hydrocarbon ring includes cyclobutane, cyclopentane, 40 
cyclohexane, cycloheptane or cyclooctane. 
26. The compound of claim 24, wherein the unsaturated 
hydrocarbon ring includes benzene, cyclopentene, 
cyclohexene, cycloheptene, cyclooctene or cyclopentadiene. 
27. The compound of claim 24, wherein the nitrogen 45 
containing heterocyclic moiety includes azetine, piperidine, 
piperazine, pyrazine, pyrazole, pyrazolidine, imidazole 
imidazoline, pyrimidine, hexa-hydropyrimidine, pyrrole, 
pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine 
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sec-butyl, isobutyl, amino, N-methylamino, N,N-
dimethylamino, carboxylate, methylcarboxylate, 
ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, 
carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, 
cyano, aminomethyl, N -methylaminomethyl, N ,N-
dimethylaminomethyl, carboxamide, 
N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, 
propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, 
methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, 
ethylthio, propiothiol, fiuoro, chloro, bromo, iodo, 
trifiuoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, 
ureido, azido, isocyanate, thioisocyanate, hydroxylamino 
and nitroso. 
33. The compound of claim 24, wherein the saturated 
hydrocarbon ring includes cyclobutane, cyclopentane, 
cyclohexane, cycloheptane or cyclooctane; the unsaturated 
hydrocarbon ring includes benzene, cyclopentene, 
cyclohexene, cycloheptene, cyclooctene or cyclopentadiene; 
the nitrogen containing heterocyclic moiety includes 
azetine, piperdine, piperazine, pyrazine, pyrazole, 
pyrazolidine, imidazole imidazoline, pyrimidine, hexa-
hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-
triazole, 1,2,4-triazole, pyridine or pyridazine; the oxygen 
containing heterocyclic moiety includes furan, 
tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 
1,4-dioxane, 1,3-dioxane or 1,4-oxathinin; the sulfur con-
taining heterocyclic moiety includes thietane, thiophene, 
thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3-
dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2-
dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium; the 
selenium containing heterocyclic moiety includes sele-
nophene; the mixed heterocycic moiety includes 
thiazolidine, thiazole or oxazin; and the substituent for the 
substituted benzene includes at least one member selected 
from the group consisting of methyl, ethyl, propyl, 
isopropyl, butyl, sec-butyl, isobutyl, amino, 
N-methylamino, N,N-dimethylamino, carboxylate, 
methylcarboxylate, ethylcarboxylate, propylcarboxylate, 
isopropylcarboxylate, carboxaldehyde, acetoxy, 
propionyloxy, isopropionyloxy, cyano, aminomethyl, 
N -methylaminomethyl, N,N -dimethylaminomethyl, 
carboxainide, N -methylcarboxamide, N ,N-
dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, 
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, 
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro, 
chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl, 
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, 
or pyridazine. 
28. The compound of claim 24, wherein the oxygen 
containing heterocyclic moiety includes furan, 
tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 
1,4-dioxane, 1,3-dioxane or 1,4-oxathinin. 
50 hydroxylamino, and nitroso. 
34. The compound of claim 24, wherein when either 
X1- Y1 or X2- Y2 is a saturated carbon-carbon bond, Y1 or 
Y2 represents CH2 , CH-OH, CHO-alkyl where said alkyl 
is a lower straight chain or branched alkyl, CH-OS02 -
C6H5, CH-OS02 -p-C6H4 CH3 , CH-SH, C6H5-SH, 
CH-S-alkyl where said alkyl is a lower straight chain or 
branched alkyl, CH-N0 2 , CH-CF3 , CH-NHOH, 
CH-OCHO, CH-F, CH-Cl, CH-Br, CH-I, 
29. The compound of claim 24, wherein the unsaturated 55 
sulfur containing heterocyclic moiety includes thietane, 
thiophene, thiophane, 2,5-dihydrothiophene, 1,3-
dithiolylium, 1,3-dithiolane, 1,2-dithiolylium, 1,2-
dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4-dithiane, or 
thiopyranylium. 60 CH-NH2 , CH-NH-alkyl where said alkyl is a lower 
straight chain or branched alkyl, CH-N(alkyl)2 alkyl where 
said alkyl is a lower straight chain or branched alkyl, 
CH-OCONH2 , CH-OCONH-alkyl where said alkyl is a 
30. The compound of claim 24, wherein the selenium 
containing heterocyclic moiety is selenophene. 
31. The compound of claim 24, wherein the mixed 
heterocyclic moiety is thiazolidine, thiazole or oxazin. 
32. The compound of claim 24, wherein the substituted 65 
benzene includes at least one substituent selected from the 
group consisting of methyl, ethyl, propyl, isopropyl, butyl, 
lower straight chain or branched alkyl, CH-OCON(alkyl)2 
where said alkyl is a lower straight chain or branched alkyl, 
CH-N3 , C=O or C=S; CH-0-phenyl, substituted 
CH-0- phenyl where the substituent is at least one 
US 6,943,177 B2 
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member selected from the group consisting of methyl, ethyl, 
propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, 
N -methylamino, N,N -dimethylamino, carboxylate, 
methylcarboxylate, ethylcarboxylate, propylcarboxylate, 
isopropylcarboxylate, carboxaldehyde, acetoxy, 5 
propionyloxy, isopropionyloxy, cyano, aminomethyl, 
N -methylaminomethyl, N ,N -dimethylaminomethyl, 
carboxamide, N-methylcarboxamide, N,N-
dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, 
sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, 10 
isopropoxy, thiol, methylthio, ethylthio, propiothiol, fiuoro, 
chloro, bromo, iodo, trifiuoromethyl, vinyl, allyl, propargyl, 
nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, 
hydroxylamino, and nitroso; or a hydrocarbon or heterocy-
clic ring comprising pyridyl, furanyl, naphthyl, thiazole, 15 
selenothenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole, 
imidazoline, pyrimidine, pyridazine or triazine. 
35. The compound of claim 24, wherein the pharmaceu-
tical salts are hydrochloride, hydrobromide, sulfate, 
hydrosulfate, citrate, fumarate and tartrate salts of said 20 
compound. 
18 
36. The method of claim 34, wherein the pharmaceutical 
salts are hydrochloride, hydro bromide, sulfate, hydrosulfate, 
citrate, fumarate and tartrate salts of said compound. 
37. The compound of claim 24, wherein said lower 
straight chain or branched alkyl contains one to seven 
carbon atoms. 
38. The method of claim 37, wherein said alkyl is methyl 
or ethyl. 
39. The method of claim 34, wherein said lower straight 
chain or branched alkyl contains one to seven carbon atoms. 
40. The method of claim 39, wherein said alkyl is methyl 
or ethyl. 
41. The compound of claim 24, wherein said compound 
is cis-2S,6R,8S-2-[ 6-~-para-toluenesulfonyloxyphenethyl)-
1-methyl-2-piperidyl ]-acetophenone. 
42. The compound of claim 24, wherein said compound 
is cis-2S,6R-N -methyl-6-[1-(2-hydroxy-2-phenyl)ethyl ]-2-
phenylethylpiperidine. 
* * * * * 
